Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Vivoryon Therapeutics N.V.
  6. Summary
    VVY   NL00150002Q7

VIVORYON THERAPEUTICS N.V.

(VVY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
07/20/2021 07/21/2021 07/22/2021 07/23/2021 07/26/2021 Date
20.4(c) 19.854(c) 19.96(c) 19.88(c) 19.322(c) Last
28 565 55 756 27 240 56 639 71 639 Volume
+1.47% -2.68% +0.53% -0.40% -2.81% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -15,9 M -18,8 M -18,8 M
Net cash position 2021 8,23 M 9,71 M 9,71 M
P/E ratio 2021 -24,3x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -10,7 M -12,6 M -12,6 M
Net Debt 2022 1,89 M 2,24 M 2,24 M
P/E ratio 2022 -35,5x
Yield 2022 -
Capitalization 386 M 456 M 456 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 18
Free-Float 69,9%
More Financials
Company
Vivoryon Therapeutics NV is a Germany based Company, that operates in the field of biotechnology. The Company offers medicines that targets post-translational modifying enzymes. It focuses on Alzheimer's disease and oncology. 
More about the company
Ratings of Vivoryon Therapeutics N.V.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about VIVORYON THERAPEUTICS N.V.
06/29VIVORYON THERAPEUTICS N : Licenses Alzheimer's Disease Drugs to China's Simcere ..
MT
06/28SIMCERE PHARMACEUTICAL : Secures License to Develop, Commercialize Vivoryon Ther..
MT
06/28VIVORYON THERAPEUTICS N.V. : Vivoryon Therapeutics Provides Update on Financial ..
EQ
06/28VIVORYON THERAPEUTICS N : and Simcere Announce Strategic Regional Licensing Part..
EQ
06/28Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd. Announce Str..
CI
06/28PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Updat..
DJ
06/28PRESS RELEASE : Vivoryon Therapeutics and Simcere Announce Strategic Regional Li..
DJ
06/28PRESS RELEASE : Vivoryon Therapeutics and Simcere -2-
DJ
06/28PRESS RELEASE : Vivoryon Therapeutics N.V.: Ordinary General Meeting of Sharehol..
DJ
06/28VIVORYON THERAPEUTICS N.V. : Ordinary General Meeting of Shareholders of Vivoryo..
EQ
06/28VIVORYON THERAPEUTICS N.V. : Press Release
CO
06/25VIVORYON THERAPEUTICS N.V. : Vivoryon Therapeutics Announces Financial Results ..
EQ
06/25PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Fina..
DJ
06/25VIVORYON THERAPEUTICS N : Announces Financial Results for the First Quarter of 2..
PU
06/25VIVORYON THERAPEUTICS N.V. : 1st quarter results
CO
More news
News in other languages on VIVORYON THERAPEUTICS N.V.
07/06Lupus kleiner in Vivoryon
06/29AMSTERDAM STOCK EXCHANGE : AEX blijft net onder record
06/29Groene koersen in Amsterdam
06/29AMSTERDAM STOCK EXCHANGE : AEX hoger van start gegaan
06/29Vivoryon kan langer door met kaspositie
More news
Chart VIVORYON THERAPEUTICS N.V.
Duration : Period :
Vivoryon Therapeutics N.V. Technical Analysis Chart | VVY | NL00150002Q7 | MarketScreener
Technical analysis trends VIVORYON THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 19,32 €
Average target price 30,50 €
Spread / Average Target 57,9%
EPS Revisions
Managers and Directors
Ulrich Dauer Chief Executive Officer & Executive Director
Florian Schmid Chief Financial Officer & Executive Director
Erich Maximilian Platzer Non-Executive Chairman
Frank T. Weber Chief Medical Officer
J÷rg Neermann Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
VIVORYON THERAPEUTICS N.V.114.45%389
MODERNA, INC.221.50%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.38.02%47 022
CELLTRION, INC.-26.46%32 170
SEAGEN INC.-18.34%28 525